Extended Use of CS 7017 Upon Completion of Participation in a Clinical Study of CS-7017 in Subjects With Cancer
This is an open-label non-randomized study of CS7017 designed to allow subjects who
completed participation in a clinical study of CS7017 without experiencing disease
progression or unacceptable toxicity to continue treatment with study drug.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate safety profile of CS-7017 treatment
United States: Food and Drug Administration
|Washington, District of Columbia|